Navigation Links
HemoShear to Present Translational Findings from its Vascular and Liver Human Relevant Systems
Date:2/21/2013

CHARLOTTESVILLE, Va., Feb. 21, 2013 /PRNewswire/ -- HemoShear LLC, a biotechnology research company and leading developer of human and animal cell-based systems for discovery and assessment of new drug compounds, will present three separate studies from its predictive human relevant systems at The Annual Society of Toxicology (SOT) meeting, being held in San Antonio, Texas, on March 10-14, 2013.  SOT is the world's largest toxicology meeting and is attended by executives and scientists who are responsible for safety assessment of a wide range of drugs, chemicals and materials. 

(Logo: http://photos.prnewswire.com/prnh/20120416/PH86899LOGO)

Each presentation provides evidence of HemoShear's ability to create physiologically accurate vascular or liver conditions that differentiate drug candidates and predict human response at in vivo-level drug doses.

Presentation Information:

DATE: March 12, 2013
ABSTRACT #: 1459
TITLE: Controlled Hemodynamics and Transport in Primary Hepatocytes Shift Induction and Toxic Responses to Drugs Closer to in vivo Concentrations
AUTHORS: Dash A, Deering T, Thomas J, Blackman BR and Wamhoff BR. 

DATE: March 12, 2013
ABSTRACT #: 1216
TITLE: Preclinical Profiling and Computational Differentiation of Human Vascular Response to 95 drugs Using NextGen RNASeq Transcriptomics
AUTHORS: Figler RA, Lawson MJ, Mackey AJ, Berzin EL, Anstey JC, Schoppee-Bortz PD, Tilghman RW, Blackman BR and Wamhoff BR.

DATE:  March 14, 2013
Late Breaking Abstract
TITLE: Human Primary Hepatocytes Under Controlled Hemodynamics Elicit Induction Responses to Drugs at Clinical Cmax Concentrations
AUTHORS: Dash A, Deering T, Marukian S, Thomas J, Blackman BR and Wamhoff BR.  HemoShear collaborator KaLy-Cell, located in Plobsheim France, provided high quality human hepatocytes and biological sample analysis for this program.  KaLy-Cell co-authors include Desbans C, Alexandre E and Richert L.

Drs. Ajit Dash and Brian Wamhoff from HemoShear will attend the SOT meeting.  For more information on the content of HemoShear's abstracts, interested parties may visit the SOT website at http://www.toxicology.org/AI/PUB/Tox/2013Tox.pdf.

About HemoShear LLC
By applying physiologically accurate hemodynamics and biological transport to primary cell cultures, HemoShear creates human-relevant systems that accurately replicate the biology of organ systems and diseases for applications throughout drug discovery and development. Working in strategic partnerships with pharmaceutical, biotechnology and medical device companies, HemoShear generates meaningful data to increase confidence in decision-making, reduce risk of costly failures and identify efficacious therapies. HemoShear's science leads to new medicines and improves human health.  

 


'/>"/>
SOURCE HemoShear LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. HemoShear Relocates and Expands Operations to Historic Martha Jefferson Property in Charlottesville, Virginia
2. HemoShear Adds Industry Veterans Mehmood Khan and Fred Brown to Board of Managers
3. HemoShear Unveils In Vitro Steatosis System at Annual Meeting of the Association for the Study of Liver Diseases
4. HemoShear Publishes Key Review on Human-Relevant Organotypic Systems
5. Masimo to Present at Raymond James 34th Annual Institutional Investors Conference
6. Express Scripts to Present at Upcoming Conferences
7. Actavis, Inc. to Present at the Cowen & Company 33rd Annual Health Care Conference
8. PAREXEL International To Present At Citi Global Healthcare Conference
9. Data Demonstrating the Safety and Efficacy of Chimerixs Antiviral CMX001 Presented at BMT Tandem Meetings
10. Oramed Pharmaceuticals to Present at the 4th Annual Drug Delivery & Formulation Summit in Berlin
11. Dr. Diana Bianchi Presents Data Demonstrating Verinata Healths Proprietary Technology Detects Genetic Abnormalities In Twin Pregnancies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... -- Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas is ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer ... they remain in the eye of the beholder, according to experts who offered insights ... American Journal of Managed Care. For the full issue, click here . , ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
Breaking Medicine News(10 mins):